Subtherapeutic anticoagulation with dabigatran following Roux-en-Y gastric bypass surgery  by Lee, Daniel et al.
CS
b
D
a
b
c
a
A
R
R
A
K
A
M
R
D
I
a
a
o
s
m
i
v
h
C
t
f
v
n
g
1
hJournal of Cardiology Cases 8 (2013) e49–e50
Contents lists available at www.sciencedirect.com
Journal  of  Cardiology  Cases
journa l h om epage: www.elsev ier .com/ locate / j ccase
ase  Report
ubtherapeutic  anticoagulation  with  dabigatran  following  Roux-en-Y  gastric
ypass  surgery
aniel  Lee  (MD)a,∗, Zachariah  DeFilipp  (MD)a, Kenneth  Judson  (DO)b,  Margaret  Kennedy  (MD)c
Department of Internal Medicine, West Penn Allegheny Health System, 320 East North Avenue, Pittsburgh, PA 15212, USA
Division of Clinical Cardiac Electrophysiology, West Penn Allegheny Health System, Pittsburgh, PA, USA
Division of Hematology and Cellular Therapy, West Penn Allegheny Health System, Pittsburgh, PA, USA
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 8 March 2013
eceived in revised form 18 March 2013
ccepted 25 March 2013
eywords:
trial ﬁbrillation
orbid obesity
oux-en-Y gastric bypass surgery
a  b  s  t  r  a  c  t
We  report  a  66-year-old  male  with  a history  of  Roux-en-Y  gastric  bypass  surgery  who  began  dabigatran
for  new  onset  atrial ﬁbrillation.  After 5 weeks  of  therapy,  his transesophageal  echocardiogram  prior  to
electrocardioversion  showed  severe  spontaneous  echo  contrast.  Cardioversion  was postponed  and  anti-
coagulant  therapy  was  continued.  The  following  day,  he  suffered  a thromboembolic  stroke.  Concern  arose
that  postoperative  malabsorption  could  have  resulted  in subtherapeutic  anticoagulation.  This  notion  was
strengthened  by  a second  patient  who  had  subtherapeutic  serum  levels  despite  maximal  dosing.  To  the
best  of our  knowledge,  we  are  the  ﬁrst  to report  impaired  absorption  of  dabigatran  following  Roux-en-Y
gastric  bypass  surgery.abigatran <Learning objective:  Dabigatran  has  a  predictable  pharmacokinetic  proﬁle,  allowing  for  a ﬁxed-dose
regimen  that  does  not  require  frequent  monitoring  or dietary  modiﬁcations.  However,  its absorption
in  patients  who  have  undergone  Roux-en-Y  gastric  bypass  surgery  has  not  been  studied.  Postoperative
malabsoprtion,  a major  complication  following  Roux-en-Y  gastric  bypass  surgery,  can  result  in  inadequate
anticoagulation.  As a result  of unpredictable  absorption,  strategies  allowing  for  routine  monitoring  may
be best  in this  population.>
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Roux-en-Y gastric bypass (RYGB) is the preferred surgical
pproach to morbid obesity because of its high level of effectiveness
nd durability. However, the procedure is associated with post-
perative malabsorptive complications. Morbid obesity carries a
igniﬁcant risk for atrial ﬁbrillation, with rates as high as 52% in
ales and 46% in females [1]. Dabigatran, an oral direct thrombin
nhibitor, is one of several novel anticoagulants approved for non-
alvular atrial ﬁbrillation. The use of dabigatran in patients who
ave undergone RYGB is not well studied.
ase report
A 66-year-old Caucasian male with diabetes mellitus, hyper-
ension, and chronic systolic congestive heart failure (ejection
raction 20%) secondary to nonischemic cardiomyopathy had pre-
iously undergone RYBG in 2001. On routine examination, he was
oted to have an irregular rhythm, conﬁrmed by electrocardio-
ram to be atrial ﬁbrillation. His CHADS2 score was 3. Given his
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normal renal function, anticoagulation was initiated with dabiga-
tran (150 mg  every 12 h). Transesophageal echocardiogram (TEE) at
that time showed severe left ventricular systolic dysfunction with
global hypokinesis. The left atrium and left ventricle were markedly
dilated, but no evidence of valvular disease or left atrial throm-
bus was seen. Therapy was  continued for 5 weeks with plans for
electrical cardioversion. However, his repeat TEE showed severe
spontaneous echo contrast throughout the left atrium and left
atrial appendage, as well as a low left atrial appendage empty-
ing velocity (20 cm/s) (Fig. 1, Video 1). He was  compliant with
anticoagulant therapy. Plans were made to continue therapy and
reassess for possible cardioversion in 6 weeks. He presented to the
emergency department the following day with left-sided weakness,
facial droop, and slurred speech. Magnetic resonance imaging (MRI)
of the brain revealed a small focus of restricted diffusion in the pos-
terior right insular cortex, consistent with acute infarction of the
right middle cerebral artery (Fig. 2). This event was thought to be
thromboembolic in nature. Coagulation studies showed partial pro-
thrombin time (PTT) 26 s (reference range: 22–34 s), prothrombin
(PT) 13.7 s (reference range: 11.4–14 s), and an international nor-
malized ratio (INR) 1.1 (reference range: 0.9–1.1). He was started
on intravenous heparin and bridged to warfarin. Fortunately, his
neurologic symptoms resolved. He has not experienced further
thromboembolic events.
vier Ltd. All rights reserved.
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Fig. 1. Transesophageal echocardiogram showing severe spontaneous echo contrast
with thrombus formation in the left atrial appendage.
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[ig. 2. Diffusion-weighted magnetic resonance image showing acute infarction in
he  right insular cortex.
A 67-year-old Caucasian female with diabetes mellitus, conges-
ive heart failure, and gastroesophageal reﬂux disease presented
ith new onset atrial ﬁbrillation, which failed electrical cardiover-
ion. She underwent RYGB in 2007. She took pantoprazole daily.
er CHADS2 score was 2 and she was started on dabigatran (150 mg
very 12 h). She continued therapy for 9 months. Given concerns
egarding the absorption of dabigatran after RYGB raised by the ﬁrst
ase, her serum trough level was measured and discovered to be
ubtherapeutic (21 ng/ml, reference range: 31–225 ng/ml) [2]. She
as transitioned to warfarin to avoid potential thromboembolic
omplications.
iscussion
Dabigatran is an increasingly popular anticoagulant being used
n the treatment of non-valvular atrial ﬁbrillation. In the RE-
Y trial, dabigatran at 150 mg  twice daily was associated with
ower rates of stroke and systemic embolism when compared to
djusted-dose warfarin [3]. Dabigatran has a predictable pharma-
okinetic proﬁle, allowing for a ﬁxed-dose regimen that does not
equire routine monitoring or dietary modiﬁcations. While direct
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thrombin inhibitors cannot be reliably monitored through tradi-
tional coagulation assays, time-dependent effects can be observed.
The anticoagulant activity of dabigatran can be reﬂected in a
prolonged PTT, although this test cannot quantify its precise antico-
agulant effect [2]. Little impact is seen on PT/INR. Most importantly,
all changes on coagulation assays are time-dependent on the most
recent dose. Peak changes are observed two hours after adminis-
tration [2].
RYGB is considered a combination restriction-malabsorption
procedure, as it involves creation of a small gastric pouch and
exclusion of the proximal small intestine from the digestive tract
[4]. Postoperative malabsorption occurs for several reasons. The
decreased intestinal length reduces time and surface area available
for absorption. Additionally, changes in gastric pH after RYGB alter
medication solubility, which can further be compounded by the
use of proton pump inhibitors and H2 blockers. Dabigatran etexi-
late, the prodrug of dabigatran, is rapidly absorbed in the stomach
and small intestine. It is coated with tartaric acid, creating an acidic
microenvironment, in an attempt to maximize absorption indepen-
dent of gastric pH [5]. Proton pump inhibitors have been shown to
decrease serum concentrations of dabigatran, although their con-
current use has not proven to be clinically signiﬁcant [6]. The extent
to which these factors affect the absorption of dabigatran following
RYGB is unclear. Nonetheless, these cases demonstrate subthera-
peutic anticoagulation, both clinically and by laboratory testing,
despite maximal dosing. As a result of unpredictable absorption,
anticoagulation strategies allowing for routine monitoring may  be
best in this population.
Conclusion
The use of dabigatran following RYGB requires further inves-
tigation due to the potentially grave consequences of impaired
absorption.
Conﬂict of interest
The authors declare no conﬂict of interest.
Appendix A. Supplementary data
Supplementary material related to this article found, in the
online version, at http://dx.doi.org/10.1016/j.jccase.2013.03.013.
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